A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBC
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Afuresertib (Primary) ; FAZ 053 (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Lung cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Laekna Therapeutics
Most Recent Events
- 10 Apr 2024 Results ( As of December 11, 2023, n=22) assessing the safety, tolerability, and anti-tumor activity of the combination therapy of LAE005 (PD-L1 antibody) plus afuresertib plus nab-paclitaxel in advanced solid tumors, primarily in TNBC presented at the 115th Annual Meeting of the American Association for Cancer Research
- 25 Aug 2023 According to a Laekna, Inc. media release, the trial completed the dose escalation phase and determined RP2D and results will be presented as an oral presentation at the Chinese Society of Clinical Oncology (CSCO) 2023 in Xiamen, China in September 2023.
- 30 May 2022 New trial record